Takeda Pharmaceutical has entered a pact with PCI Pharma Services, a Philadelphia, Pennsylvania-headquartered pharmaceutical services provider, for the development, manufacture, clinical-trial-supply and US commercial launch of Takeda’s lung cancer drug, Alunbrig (brigatinib).

Alunbrig, a once-daily tablet, is a kinase inhibitor indicated for treating anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in patients who have progressed on or are intolerant to crizotinib, the active ingredient in Pfizer’s cancer drug, Xalkori.

PCI provided the development and manufacturing services from its high-containment manufacturing facility in Tredega, UK.

Source: PCI Pharma Services